Gabapentin Tablet
Product Images NDC 60760-743

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-743). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gab (Gabapentin 60760 743 90)

Gabapentin Tablets, USP 600 mg oral tablets in a 90-count package. The label displays the NDC 60760-743-90 and indicates it is manufactured by ScienGen Pharmaceuticals, Inc. and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes instructions to use as directed and storage information to keep at controlled room temperature (15°-30°C).*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph illustrating the mean pain score over 7 weeks during a clinical study with a 3-week dose titration period followed by a 4-week fixed dose period. It compares placebo to gabapentin at dosages of 1800 mg/day and 2400 mg/day, showing pain score changes from baseline to week 7.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders at Endpoint: Controlled PHN Studies' showing the percentage of patients with 50% or greater pain score reduction in two studies. Study 1 compares PBO (12%) and GBP 3600 (29%). Study 2 compares PBO (14%), GBP 1800 (32%), and GBP 2400 (34%). Statistical significance is indicated for GBP groups versus PBO.*

FDA Label Image

Image-04 (Image 04)

An anatomical or medical diagram showing the formula to calculate creatinine clearance (CLCr) based on age, weight, serum creatinine, and gender adjustment. The formula includes age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of the active ingredient Gabapentin, showing a cyclohexane ring with an amino group and a carboxymethyl group attached.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot showing the percentage difference on the y-axis versus daily dose in mg on the x-axis for Gabapentin. The plot includes data points for three studies labeled 'STUDY a,' 'STUDY b,' and 'STUDY c' across daily doses of 600, 900, 1200, and 1800 mg. Each study is represented by a distinct square marker with corresponding labels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.